Drug testing has two distinct origin stories: one in sports and one in the workplace. Organized drug testing first began at the 1968 Olympic Games in Mexico City, when athletes were required to provide urine samples for the first time. Workplace drug testing in the United States followed nearly two decades later, launched by a 1986 executive order targeting federal employees. Both tracks have expanded dramatically since then.
The 1960s: Sports Testing Comes First
The push for drug testing started with tragedy. A Danish cyclist died at the 1960 Rome Olympics, allegedly after taking amphetamines. Seven years later, a cyclist died during the Tour de France under similar circumstances. These deaths pushed the International Olympic Committee to establish a Medical Commission and, in 1967, create its first list of prohibited substances. That list initially covered only stimulants and narcotics, the two drug classes that could be reliably detected in urine at the time.
Starting in 1968, Olympic athletes were required to submit urine samples, called “doping controls.” The first person ever disqualified under these new rules was Swedish pentathlete Hans-Gunnar Liljenwall, who drank two beers before his pistol shooting event to calm his nerves. Alcohol appeared on at least one restricted substance list that year, and the entire Swedish team was forced to return their bronze medals.
1986: The Federal Workplace Era Begins
Workplace drug testing in the U.S. traces back to September 15, 1986, when President Ronald Reagan signed Executive Order 12564, declaring the federal government would be a “drug-free workplace.” The order stated flatly that people who use illegal drugs “are not suitable for Federal employment” and that illegal drug use by federal employees, whether on or off duty, was “contrary to the efficiency of the service.”
The order required every executive branch agency to develop a plan that included a clear drug-use policy, employee assistance programs with counseling and rehabilitation referrals, supervisory training to identify drug use, and a provision for drug testing “on a controlled and carefully monitored basis.” This was the foundation that made large-scale workplace testing possible.
1988: Standardized Testing Takes Shape
Two key developments in 1988 turned Reagan’s executive order into a functioning system. On April 11, 1988, the Department of Health and Human Services published the first Mandatory Guidelines for Federal Workplace Drug Testing Programs. These guidelines, administered through what is now SAMHSA (the Substance Abuse and Mental Health Services Administration), created a scientific and technical framework for how testing would work across all civilian positions in executive branch agencies. They established the standard five-panel urine test, screening for marijuana, cocaine, amphetamines, opiates, and PCP.
Later that year, on November 18, Congress passed the Drug-Free Workplace Act of 1988. This law extended requirements beyond direct federal employees: any organization receiving a federal contract or grant had to certify it would maintain a drug-free workplace as a condition of that funding. The law applied to prime grantees, though not to subgrantees. This single provision pulled thousands of private employers into the drug-testing ecosystem for the first time.
1991: Transportation Workers Get Covered
Congress passed the Omnibus Transportation Employee Testing Act in 1991, which mandated drug and alcohol testing for workers in safety-sensitive transportation roles. This covered aviation, trucking, railroads, mass transit, pipelines, and maritime operations. The logic was straightforward: a bus driver or airline pilot under the influence posed a direct risk to public safety. The Department of Transportation developed detailed regulations under this act, requiring pre-employment testing, random testing, post-accident testing, and reasonable-suspicion testing for millions of transportation workers.
How the Technology Evolved
Early drug tests were limited by what labs could actually detect. The standard approach that emerged in the late 1980s relied on immunoassay screening, a technique that uses antibodies to flag the presence of drug compounds in urine. This became the backbone of the SAMHSA-5 panel. Because immunoassay tests can produce false positives, a two-step process became standard: an initial immunoassay screen followed by a more precise confirmation using gas chromatography-mass spectrometry, which can identify the exact chemical structure of a substance.
For decades, urine remained the only specimen type approved for federal testing. Oral fluid (saliva) guidelines were published by SAMHSA in 2019, and proposed guidelines for hair testing followed in 2020. As of the most recent federal updates, however, no federal agencies have actually implemented hair or oral fluid testing.
What the Standard Test Looks Like Now
The federal testing panel is getting its most significant update in years, effective July 7, 2025. The biggest change: fentanyl is being added to both the urine and oral fluid panels, reflecting the drug’s role in the current overdose crisis. The urine test will screen for fentanyl and its metabolite norfentanyl at a cutoff of just 1 nanogram per milliliter, an extremely sensitive threshold.
The updated panel still tests for marijuana (with updated scientific abbreviations for its analytes), cocaine, amphetamines and methamphetamine, opiates, and PCP. The government considered removing MDMA and MDA (ecstasy and its related compound) from the panel but decided those drugs need further study before any removal. So for now, they stay.
From two beers at the 1968 Olympics to nanogram-level fentanyl detection in 2025, drug testing has expanded from a narrow sporting concern into a system that touches millions of American workers every year. The core technology, urine immunoassay followed by lab confirmation, has remained remarkably consistent since the late 1980s, even as the list of targeted substances continues to grow.